StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.36−0.61 (-1.00%)

Close on Nov 17, 2026Market cap $5.04BP/E –Yield –

PTC Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

PTC Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was $10.49M, down 98.5% year over year. For fiscal 2025 it was $711.20M. The highest annual figure on record is $711.20M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$711.20M–
FY2024Dec 31, 2024-$107.69M–
FY2023Dec 31, 2023-$158.42M–
FY2022Dec 31, 2022-$356.65M–
FY2021Dec 31, 2021-$251.33M–
FY2020Dec 31, 2020-$194.07M–
FY2019Dec 31, 2019-$98.64M–
FY2018Dec 31, 2018-$27.64M–
FY2017Dec 31, 2017-$10.06M–
FY2016Dec 31, 2016-$103.57M–
FY2015Dec 31, 2015-$124.34M–
FY2014Dec 31, 2014-$57.27M–
FY2013Dec 31, 2013-$46.92M–
FY2012Dec 31, 2012-$47.93M–
FY2011Dec 31, 2011-$20.77M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.31M–
Q2 FY2026Jun 30, 2026$129.11M–
Q1 FY2026Mar 31, 2026-$59.04M-106.8%
Q4 FY2025Dec 31, 2025-$34.27M–
Q3 FY2025Sep 30, 2025-$66.30M–
Q2 FY2025Jun 30, 2025-$58.33M–
Q1 FY2025Mar 31, 2025$870.10M+1129.6%
Q4 FY2024Dec 31, 2024-$30.00M–
Q3 FY2024Sep 30, 2024-$76.99M–
Q2 FY2024Jun 30, 2024-$71.45M–
Q1 FY2024Mar 31, 2024$70.76M–
Q4 FY2023Dec 31, 2023-$100.29M–
Q3 FY2023Sep 30, 2023-$14.52M–
Q2 FY2023Jun 30, 2023-$14.12M–
Q1 FY2023Mar 31, 2023-$29.49M–
Q4 FY2022Dec 31, 2022-$165.96M–
Q3 FY2022Sep 30, 2022-$38.05M–
Q2 FY2022Jun 30, 2022-$55.24M–
Q1 FY2022Mar 31, 2022-$97.40M–
Q4 FY2021Dec 31, 2021-$68.84M–
Q3 FY2021Sep 30, 2021-$51.19M-292.0%
Q2 FY2021Jun 30, 2021-$31.15M–
Q1 FY2021Mar 31, 2021-$100.16M–
Q4 FY2020Dec 31, 2020-$64.37M–
Q3 FY2020Sep 30, 2020$26.66M–
Q2 FY2020Jun 30, 2020-$74.81M–
Q1 FY2020Mar 31, 2020-$81.55M–
Q4 FY2019Dec 31, 2019-$10.21M–
Q3 FY2019Sep 30, 2019-$15.50M-559.0%
Q2 FY2019Jun 30, 2019-$30.52M-1017500.0%
Q1 FY2019Mar 31, 2019-$42.41M–
Q4 FY2018Dec 31, 2018-$15.14M-171.1%
Q3 FY2018Sep 30, 2018$3.38M–
Q2 FY2018Jun 30, 2018$3.00K-100.0%
Q1 FY2018Mar 31, 2018-$15.88M–
Q4 FY2017Dec 31, 2017$21.29M–
Q3 FY2017Sep 30, 2017-$15.77M–
Q2 FY2017Jun 30, 2017$13.32M–
Q1 FY2017Mar 31, 2017-$28.90M–
Q4 FY2016Dec 31, 2016-$13.32M–

More PTC Therapeutics figures

See a number that looks wrong?